18-002 - Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Status: openA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy - SWOG S1418 (BR0006)
Treatment for Breast Cancer
Description
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Sponsors
This trial is sponsored by SWOG.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
View Profile
Teja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology